CTOs on the Move

BrainsWay

www.brainsway.com

 
BrainsWay is an Israeli company with international operations that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a noninvasive treatment for depression.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.brainsway.com
  • 1 Van de Graaff Drive Suite 405
    Burlington, MA USA 01803
  • Phone: 844.386.7001

Executives

Name Title Contact Details

Similar Companies

Olema

Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.

myMatrixx

myMatrixx is a full-service pharmacy benefit management (PBM) and ancillary services company focused on workers’ compensation. By combining advanced technology and proactive clinical management throughout the claims process, myMatrixx delivers a Fast, Simple, Effective solution with proven Results. Founded in 2001 by Steven MacDonald, an industry veteran in workers’ compensation, myMatrixx began as a pharmacy benefit manager. Today services include a corporately-owned and operated mail service pharmacy with compounding, ancillary services and DME, and proactive clinical programs. With a focus on workers’ compensation, myMatrixx serves self-insured employers, third party administrators, managed care companies, as well as workers’ compensation and auto insurance companies. From the beginning, we have put the client at the center of everything we do. Their success is our success, and delivering an unimaginably great customer experience is our goal.  

Institute for Therapy through the Arts

The Institute for Therapy through the Arts offers art therapy, music therapy, dance therapy, and drama therapy in Evanston, IL 60201 and Chicagoland.

Sydnexis,

Sydnexis Inc. is a clinical stage biopharmaceutical company based in San Diego. They are currently evaluating their patented eyedrop formulation, SYD 101, in a Phase 3 clinical trial to decrease myopia progression in children.